Andrew E. Scanga

Andrew E. Scanga

Auto-generated profile, based on publicly available information

Andrew E. Scanga

Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2022 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
KMKelly L. Mishra
Kelly L. Mishra
MBMichael T. Baker
Michael T. Baker
KSKara K. Siegrist
Kara K. Siegrist
ALAlice Liao
Alice Liao
ASAndrew E. Scanga
Andrew E. Scanga
LMLisa A. Mendes
Lisa A. Mendes

31 December 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
ABAnna O. Basile
Anna O. Basile
AVAnurag Verma
Anurag Verma
LTLeigh Anne Tang
Leigh Anne Tang
MSMarina Serper
Marina Serper
ASAndrew Scanga
Andrew Scanga
JWJulia Wattacheril
Julia Wattacheril
Nonalcoholic fatty liver disease (NAFLD) is the most common global cause of chronic liver disease and remains under‐recognized within healthcare systems. Therapeutic interventions are rapidly advancing for its inflammatory phenotype, nonalcoholic steatohepatitis (NASH) at all stages of disease. Diagnosis codes alone fail to recognize and stratify at‐risk patients accurately. Our work aims to rapidly identify NAFLD patients within large electronic health record (EHR) databases for automated stratification and targeted intervention based on clinically relevant phenotypes. We present a rule‐based phenotyping algorithm for efficient identification of NAFLD patients developed using EHRs from 6.4 million patients at Columbia University Irving Medical Center (CUIMC) and validated at two independent healthcare centers. The algorithm uses the Observational Medical Outcomes Partnership (OMOP) Common Data Model and queries structured and unstructured data elements, including diagnosis codes, laboratory measurements, and radiology and pathology modalities. Our approach identified 16,006 CUIMC NAFLD patients, 10,753 (67%) previously unidentifiable by NAFLD diagnosis codes. Fibrosis scoring on patients without histology identified 943 subjects with scores indicative of advanced fibrosis (FIB‐4, APRI, NAFLD–FS). The algorithm was validated at two independent healthcare systems, University of Pennsylvania Health System (UPHS) and Vanderbilt Medical Center (VUMC), where 20,779 and 19,575 NAFLD patients were identified, respectively. Clinical chart review identified a high positive predictive value (PPV) across all healthcare systems: 91% at CUIMC, 75% at UPHS, and 85% at VUMC, and a sensitivity of 79.6%. Our rule‐based algorithm provides an accurate, automated approach for rapidly identifying, stratifying, and sub‐phenotyping NAFLD patients within a large EHR system.